All relevant data are within the paper, its Supporting Information files and the Harvard Dataverse Databank with the following DOI: [10.7910/DVN/T4KPQI](https://doi.org/10.7910/DVN/T4KPQI).

Introduction {#sec001}
============

The current American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines recommend 6-month dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation in patients with stable coronary artery disease (CAD).\[[@pone.0227612.ref001],[@pone.0227612.ref002]\] On the other hand, DAPT has been recommended for at least 1 year in patients with acute coronary syndrome (ACS), irrespective of the revascularization strategies and stent types. However, due to the paucity of dedicated randomized trials or prospective trial evaluating short DAPT in patients with ACS, the optimal duration of DAPT after DES implantation in ACS is still a matter of debate.

We previously reported the favorable outcomes of those patients treated with 3-month DAPT after cobalt-chromium everolimus-eluting stent (CoCr-EES) in the STOPDAPT (ShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent) trial as compared with those enrolled in the historical control of RESET (Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial) study, in which nearly 90% of patients had continued DAPT at 1-year. \[[@pone.0227612.ref003],[@pone.0227612.ref004]\] The STOPDAPT trial included a substantial proportion of patients with ACS. Therefore, we sought to evaluate the safety of 3-month DAPT duration after CoCr-EES implantation in those with ACS as compared with those with stable CAD.

Methods {#sec002}
=======

Study population {#sec003}
----------------

STOPDAPT trial is a prospective multi-center single-arm trial enrolling patients who agreed to follow the 3-month DAPT protocol (discontinuation of clopidogrel at 2- to 4-month and aspirin monotherapy thereafter) after successful CoCr-EES implantation in all-comer population.\[[@pone.0227612.ref003]\] Patients who underwent successful percutaneous coronary intervention (PCI) using CoCr-EES were to be enrolled, if the physicians in charge judged the patient to be eligible for the study evaluating 3-month DAPT duration. Patients who had previous history of PCI using DES other than CoCr-EES were excluded.

Between September 2012 and October 2013, 6070 patients underwent PCI using CoCr-EES in 58 Japanese centers (List A in [S1 Appendix](#pone.0227612.s005){ref-type="supplementary-material"}). We excluded 2490 patients who were previously treated with DES other than CoCr-EES. Among 3580 eligible patients, 1526 patients (43%) were enrolled in this study. Excluding 1 patient who withdrew consent for study participation, 1525 patients constituted the current study population. Among 1525 patients, 487 patients presented as ACS and 1038 patients had stable CAD ([Fig 1](#pone.0227612.g001){ref-type="fig"}). Complete 1-year clinical follow-up was achieved in 1519 patients (99.6%). We compared the clinical outcomes between ACS and stable CAD patients.

![Study flow chart.\
CoCr-EES, Cobalt-chromium everolimus-eluting stent; DES, drug-eluting stent; ACS, acute coronary syndrome; CAD, coronary artery disease.](pone.0227612.g001){#pone.0227612.g001}

As a historical control group, we selected the CoCr-EES group in the RESET trial (a randomized controlled trial comparing CoCr-EES with sirolimus-eluting stent conducted by the same study group in 2010), where nearly 90% of patients had continued DAPT at 1-year.\[[@pone.0227612.ref004]\] The eligibility criteria of the RESET was comparable to that of the STOPDAPT except for the inclusion of patients with previous DES implantation in the RESET. Among 1597 patients in the CoCr-EES group in the RESET, 38 patients with in-hospital primary endpoint events were excluded from the historical control group in this study, because patients in the STOPDAPT were enrolled after completion of successful PCI. A total of 1559 patients were selected as a historical control group.\[[@pone.0227612.ref003]\]

Ethics {#sec004}
------

The research protocol of the STOPDAPT trial ([S1 Protocol](#pone.0227612.s004){ref-type="supplementary-material"}) was approved by the Institutional Review Board in Kyoto University and by the local ethics committees in all of 58 participating medical centers (List A in [S1 Appendix](#pone.0227612.s005){ref-type="supplementary-material"}) (ClinicalTrials.gov: NCT 01659034). Written informed consent was obtained from all the study patients.

Procedures {#sec005}
----------

Antiplatelet regimen included aspirin (≥81mg daily) indefinitely and thienopyridine (75mg clopidogrel daily) for 3-month after stent implantation. Ticlopidine 200 mg/day was only allowed for those who did not tolerate clopidogrel. Patients were instructed to discontinue thienopyridine at 3-month hospital visit. Acceptable time window for the discontinuation of thienopyridine therapy was within ±1 month. DAPT duration in patients with oral anticoagulants was the same as the rest of the population. Status of antiplatelet therapy was evaluated throughout the follow-up period as previously described.\[[@pone.0227612.ref005]\] Persistent discontinuation of thienopyridine was defined as withdrawal lasting for at least 2 months.\[[@pone.0227612.ref005]\]

Endpoints and definitions {#sec006}
-------------------------

ACS included those patients who presented as ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA) at the time of index PCI. The remaining study patients other than ACS were regarded as having stable CAD. STEMI was defined as those with an increase of cardiac biomarker with persistent ST-segment elevation or new Q-wave in electrocardiogram. NSTEMI was defined as those with an increase of cardiac biomarker without electrocardiogram changes of STEMI. High-sensitivity troponin or CK-MB value \> upper reference limit were diagnosed as MI in the all participating centers. UA was defined as those with anginal pain of Braunwald class I-III with no increase of a cardiac biomarker.\[[@pone.0227612.ref006]\] The Global Registry of Acute Coronary Events (GRACE) score was calculated in patients with ACS.\[[@pone.0227612.ref007]\] The primary endpoint in this trial was a composite of cardiovascular death, myocardial infarction (MI), stroke, definite stent thrombosis (ST) and Thrombolysis in Myocardial Infarction (TIMI) major/minor bleeding at 1 year. Primary endpoint events were adjudicated by the independent clinical event committee (List B in [S1 Appendix](#pone.0227612.s005){ref-type="supplementary-material"}). Major secondary endpoints were TIMI major/minor bleeding and a composite of cardiovascular death, MI, stroke or definite ST at 1 year. Other secondary endpoints included death, MI, stroke, possible/probable/definite ST, bleeding events defined by TIMI or Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) criteria,\[[@pone.0227612.ref008],[@pone.0227612.ref009]\] target-lesion revascularization (TLR), target-vessel revascularization (TVR), coronary artery bypass grafting and any coronary revascularization.

Death was regarded as cardiac in origin unless obvious non-cardiac causes could be identified. MI and ST were defined according to the Academic Research Consortium definitions.\[[@pone.0227612.ref010]\] Stroke during follow-up was defined as ischemic or hemorrhagic stroke requiring hospitalization with symptoms lasting \>24 hours. TLR was defined as either PCI or coronary artery bypass grafting due to restenosis or thrombosis of the target lesion that included the proximal and distal edge segments as well as the ostium of the side branches. Patients with planned staged PCI were enrolled in this study after the completion of all the planned coronary revascularization procedures. Therefore, scheduled staged PCI procedures were not included in any coronary revascularization during follow-up.

Data collection and follow-up {#sec007}
-----------------------------

Demographic, angiographic, and procedural data were collected from hospital charts or databases in each participating center according to the pre-specified definitions by experienced clinical research coordinators in the participating centers (List B in [S1 Appendix](#pone.0227612.s005){ref-type="supplementary-material"}) or in the study management center (List B in [S1 Appendix](#pone.0227612.s005){ref-type="supplementary-material"}). Follow-up data on the clinical events were collected from the hospital charts in the participating centers (74%), letters to patients (20%), and telephone call to referring physicians (8.4%).

Statistical analysis {#sec008}
--------------------

Categorical variables were presented as number and percentage, and were compared with the chi-square test or the Fisher's exact test. Continuous variables were expressed as mean value ± SD or median with inter-quartile range, and were compared using the Student's t test or Wilcoxon rank sum test based on their distributions. As the main analysis in the present study, clinical outcomes were compared between the ACS patients and the stable CAD patients in the STOPDAPT trial. Cumulative incidence was estimated by the Kaplan-Meier method and differences were assessed with the log-rank test. To evaluate the events beyond 3-month, we also conducted the landmark analyses at 3-month. Those patients who had the individual endpoint events before 3-month were excluded in the landmark analyses. Due to the presence of differences in baseline characteristics between the 2 groups, we used multivariable Cox proportional hazard models to estimate the risk of patients with ACS relative to those with stable CAD for the primary endpoint. In the multivariable analysis, we chose 7 clinically relevant factors indicated in [Table 1](#pone.0227612.t001){ref-type="table"} as the risk adjusting variables (age \> = 75 years, diabetes, hemodialysis, atrial fibrillation, prior MI, peripheral vascular disease, and statins use). The continuous variables were dichotomized by clinically meaningful reference values or median values. The presentation (ACS or stable CAD), the 7 risk-adjusting variables and random effect of center were simultaneously included in the Cox proportional hazard model. Proportional hazard assumptions for the risk-adjusting variables were assessed on the plots of log (time) versus log \[-log (survival)\] stratified by the variable. The assumptions were verified to be acceptable for all the variables. The effect of ACS relative to stable CAD for the primary endpoint was expressed as hazard ratios (HR) and their 95% confidence intervals (CI). As the sensitivity analyses, we conducted propensity matched analysis. The propensity score was calculated from the 7 risk-adjusting variables. Using the propensity score, patients in the stable CAD group were randomly matched to ACS patients using a greedy matching strategy. Sample size calculation for the main analysis of this study was previously described. \[[@pone.0227612.ref003]\]

10.1371/journal.pone.0227612.t001

###### Baseline characteristics: ACS versus stable CAD.

![](pone.0227612.t001){#pone.0227612.t001g}

                                                                          ACS            Stable CAD       P Value
  ----------------------------------------------------------------------- -------------- ---------------- ----------
  **Clinical characteristics**                                                                            
  Age--years                                                              69.0±12.3      70.5±9.7         0.009
      Age \> = 75 years [\*](#t001fn002){ref-type="table-fn"}             176 (36%)      394 (38%)        0.49
  Men                                                                     361 (74%)      756 (73%)        0.59
  Body mass index                                                         24.0±3.6       24.2±3.5         0.21
  Coexisting condition                                                                                    
      Hypertension                                                        406 (83%)      855 (82%)        0.63
      Diabetes mellitus [\*](#t001fn002){ref-type="table-fn"}             162 (33%)      442 (43%)        0.0005
        Insulin-treated diabetes                                          18 (3.7%)      101 (9.7%)       \<0.0001
        Treated with oral medication only                                 91 (19%)       269 (26%)        0.002
        Treated with diet therapy only                                    53 (11%)       72 (6.9%)        0.01
      Dyslipidemia                                                        386 (79%)      823 (79%)        0.99
      ESRD (eGFR\<30 mL/min/1.73m^2^) not on HD                           16 (3.3%)      19/1034 (1.8%)   0.09
      HD [\*](#t001fn002){ref-type="table-fn"}                            8 (1.6%)       48 (4.6%)        0.002
      Atrial fibrillation [\*](#t001fn002){ref-type="table-fn"}           39 (8.0%)      133 (13%)        0.005
      Anemia (Hemoglobin \<11.0 g/dL)                                     76 (16%)       165 (16%)        0.88
  Cardiac risk factor                                                                                     
      Current smoker                                                      142 (29%)      173 (17%)        \<0.0001
      Family history of coronary artery disease                           58 (12%)       134 (13%)        0.58
      Prior myocardial infarction [\*](#t001fn002){ref-type="table-fn"}   38 (7.8%)      229 (22%)        \<0.0001
      Prior Stroke                                                        49 (10%)       119 (11%)        0.41
      Heart failure                                                       58 (12%)       147 (14%)        0.23
      Peripheral vascular disease [\*](#t001fn002){ref-type="table-fn"}   19 (3.9%)      123 (12%)        \<0.0001
      Prior percutaneous coronary intervention                            80 (16%)       388 (37%)        \<0.0001
      Prior coronary-artery bypass grafting                               6 (1.2%)       35 (3.4%)        0.01
  Clinical characteristics                                                                                
      Clinical presentation                                                                               
        Unstable angina                                                   228 (47%)                       
        Acute myocardial infarction                                       259 (53%)                       
        STEMI                                                             215 (44%)                       
          NSTEMI                                                          44 (9.0%)                       
      GRACE score                                                                                         
        Unstable angina                                                   109.4±27.0                      
        STEMI                                                             159.6±32.1                      
          NSTEMI                                                          123.8±32.5                      
      Left ventricular ejection fraction \<30%                            4/419 (1.0%)   13/896 (1.5%)    0.45
      Multivessel disease                                                 141 (29%)      437 (42%)        \<0.0001
  Target vessel location                                                                                  
      Left main coronary artery                                           4 (0.8%)       13 (1.3%)        0.44
      Left anterior descending coronary artery                            299 (61%)      567 (55%)        0.01
      Left circumflex coronary artery                                     85 (17%)       276 (27%)        \<0.0001
      Right coronary artery                                               125 (26%)      280 (27%)        0.59
      Bypass graft                                                        1 (0.2%)       3 (0.3%)         0.76
  Complexity of coronary artery disease                                                                   
      No. of treated lesions per patient                                  1.14±0.42      1.24±0.5         \<0.0001
  Medications                                                                                             
      Aspirin                                                             487 (100%)     1037 (99.9%)     0.38
      Thienopyridines                                                     487 (100%)     1035 (99.7%)     0.13
        Clopidogrel                                                       485 (99.6%)    1023 (98.8%)     0.13
        Ticlopidine                                                       2 (0.4%)       12 (1.2%)        
      Statins [\*](#t001fn002){ref-type="table-fn"}                       438 (90%)      785 (76%)        \<0.0001
        Strong statins[\*\*](#t001fn003){ref-type="table-fn"}             407 (84%)      706 (68%)        \<0.0001
        Maximum approved doses of strong statin                           7 (1.4%)       20 (1.9%)        0.49
      B-blockers                                                          256 (53%)      364 (35%)        \<0.0001
      ACE-I/ARB                                                           334 (69%)      605 (58%)        0.0001
      Calcium-channel blockers                                            164 (34%)      511 (49%)        \<0.0001
      Nitrates                                                            65 (13%)       154 (15%)        0.44
      Anticoaglants                                                       45 (9.2%)      123 (12%)        0.12
        Warfarin                                                          38 (7.8%)      87 (8.4%)        0.7
        Dabigatran                                                        5 (1.0%)       29 (2.8%)        0.02
        Rivaroxaban                                                       2 (0.4%)       7 (0.7%)         0.52
  **Lesion and procedural characteristics**                                                               
      Before index procedure                                                                              
        Chronic total occlusion                                           7 (1.4%)       65 (6.3%)        \<0.0001
        Culprit for STEMI                                                 202 (41%)                       
        Bifurcation                                                       105 (22%)      212 (20%)        0.61
      After index procedure                                                                               
        No. of stents used per patient                                    1.27±0.56      1.42±0.68        \<0.0001
        Total stent length per patient---mm                               30.7±18.0      33.9±22.1        0.09
      Multivessel treatment                                               28 (5.8%)      102 (9.8%)       0.006

Values are expressed as mean ± SD or number (%).

\* Risk-adjusting variables selected for multivariable analysis.

\*\* Atorvastatin, pitavastatin and rosuvastatin were considered to be strong statins.

ACS = acute coronary syndrome; CAD = coronary artery disease; ESRD = end stage renal disease; eGFR = estimated glomerular filtration rate; HD = hemodialysis; STEMI = ST-segment elevation myocardial infarction; NSTEMI = non-ST-segment elevation myocardial infarction; The Global Registry of Acute Coronary Events (GRACE); ACE-I = angiotensin converting enzyme inhibitors; ARB = angiotensin II receptor blockers.

Statistical analyses were conducted by a physician (Natsuaki M) and a statistician (Morimoto T) with the use of JMP 10.0 software. We used 2-sided P values \<0.05 as statistically significant.

Results {#sec009}
=======

Baseline characteristics: Enrolled versus non-enrolled patients in the STOPDAPT {#sec010}
-------------------------------------------------------------------------------

Baseline characteristics were significantly different in several aspects between the enrolled and non-enrolled patients ([S1 Table](#pone.0227612.s001){ref-type="supplementary-material"}). AMI presentation were more prevalent in the non-enrolled group, while stable CAD were more often found in the enrolled group.

Baseline characteristics: ACS versus stable CAD {#sec011}
-----------------------------------------------

In ACS group, 44% of patients presented as STEMI, 9% of patients presented as NSTEMI and 47% of patients had UA. Baseline characteristics were significantly different in several aspects between the ACS and stable CAD groups ([Table 1](#pone.0227612.t001){ref-type="table"}). Patients in the ACS group were significantly younger than those in the stable CAD group. The ACS group more often had current smoker, while the stable CAD group more often had diabetes, hemodialysis, atrial fibrillation, prior MI, peripheral vascular disease, prior PCI, prior coronary artery bypass grafting and multi-vessel disease. The ACS group more often included treatment of left anterior descending artery, while the stable CAD group more often included treatment of left circumflex artery and chronic total occlusion. The stable CAD group had greater number of stents per patient, and longer total stent length per patient than the ACS group. Multi-vessel treatment was more often performed in the stable CAD group than in the ACS group. Regarding the medications at hospital discharge, statins, β-blockers and angiotensin converting enzyme inhibitors/angiotensin II receptor blockers were more often prescribed in the ACS group than in the non-ACS group. Maximum approved doses of strong statins were very infrequently implemented ([Table 1](#pone.0227612.t001){ref-type="table"}).

Discontinuation of thienopyridine {#sec012}
---------------------------------

Thienopyridine was discontinued within 4-month in 455 patients (94.0%) in the ACS group and 977 patients (94.3%) in the stable CAD group. Cumulative 1-year incidence of persistent discontinuation of thienopyridine was 96.7% in the ACS group and 96.8% in the stable CAD group (P = 0.34) ([Fig 2](#pone.0227612.g002){ref-type="fig"}).

![Cumulative incidence of persistent discontinuation of thienopyridine.\
ACS, acute coronary syndrome; CAD, coronary artery disease; PCI, percutaneous coronary intervention.](pone.0227612.g002){#pone.0227612.g002}

Clinical outcomes through 1-year {#sec013}
--------------------------------

Cumulative 1-year incidence of the primary endpoint was very low and not significantly different between the ACS and stable CAD groups (2.3% versus 3.0%, P = 0.42) ([Fig 3](#pone.0227612.g003){ref-type="fig"} and [Table 2](#pone.0227612.t002){ref-type="table"}). In the multivariable analysis, there was no excess risk of the ACS group relative to the stable CAD group for the primary endpoint (adjusted HR 0.94, 95% CI 0.44--1.87, P = 0.87) ([Table 3](#pone.0227612.t003){ref-type="table"}). Regarding the major secondary endpoints, the cumulative incidences of TIMI major/minor bleeding and a composite of cardiovascular death, MI, stroke and definite ST were also not significantly different between the ACS and stable CAD groups. There was no definite/probable ST through 1-year after PCI in both groups ([Fig 4](#pone.0227612.g004){ref-type="fig"}).

![Cumulative incidence of the primary endpoint.\
Primary endpoint was defined as a composite of cardiovascular death, MI, stroke, definite ST and TIMI major/minor bleeding. MI, myocardial infarction; ST, stent thrombosis; TIMI, Thrombolysis in Myocardial Infarction; ACS, acute coronary syndrome; CAD, coronary artery disease; PCI, percutaneous coronary intervention.](pone.0227612.g003){#pone.0227612.g003}

![Clinical outcomes at 1-year.\
Event rates indicated the cumulative 1-year incidence estimated by Kaplan-Meier method. Primary endpoint was defined as a composite of CV death, MI, stroke, definite ST and TIMI major/minor bleeding. ACS, acute coronary syndrome; CAD, coronary artery disease; CV death, cardiovascular death; MI, myocardial infarction; ST, stent thrombosis; TIMI, Thrombolysis in Myocardial Infarction.](pone.0227612.g004){#pone.0227612.g004}

10.1371/journal.pone.0227612.t002

###### Clinical outcomes at 12-month.

![](pone.0227612.t002){#pone.0227612.t002g}

                                                    No. of patients with at least one event   P Value     
  ------------------------------------------------- ----------------------------------------- ----------- ------
  Primary Endpoint                                  11 (2.3%)                                 31 (3.0%)   0.42
  Death                                                                                                   
      All-cause                                     5 (1.0%)                                  25 (2.4%)   0.07
      Cardiac death                                 2 (0.4%)                                  7 (0.7%)    0.53
      Cardiovascular death                          2 (0.4%)                                  8 (0.8%)    0.42
      Non-cardiac death                             3 (0.6%)                                  18 (1.7%)   0.08
  Myocardial infarction                             1 (0.2%)                                  3 (0.3%)    0.76
  Stroke                                                                                                  
      Any                                           4 (0.8%)                                  13 (1.3%)   0.45
      Ischemic                                      3 (0.6%)                                  11 (1.1%)   0.4
      Hemorrhagic                                   2 (0.4%)                                  2 (0.2%)    0.44
  Bleeding                                                                                                
      TIMI major                                    4 (0.8%)                                  8 (0.8%)    0.92
      TIMI minor/major                              6 (1.2%)                                  9 (0.9%)    0.5
      TIMI minimal/minor/major                      14 (2.9%)                                 23 (2.2%)   0.44
      GUSTO severe                                  4 (0.8%)                                  6 (0.6%)    0.59
      GUSTO moderate/severe                         4 (0.8%)                                  12 (1.2%)   0.55
  Definite stent thrombosis                         0 (0%)                                    0 (0%)      
  Stent thrombosis                                                                                        
      Possible                                      0 (0%)                                    6 (0.6%)    0.09
      Probable                                      0 (0%)                                    0 (0%)      
      Definite or probable                          0 (0%)                                    0 (0%)      
      Definite, probable or possible                0 (0%)                                    6 (0.6%)    0.09
  Death or myocardial infarction                    6 (1.2%)                                  28 (2.7%)   0.07
  Cardiovascular death or myocardial infarction     3 (0.6%)                                  11 (1.1%)   0.4
  Cardiovascular death, MI or stroke                7 (1.4%)                                  24 (2.3%)   0.26
  Cardiovascular death, MI, stroke or definite ST   7 (1.4%)                                  24 (2.3%)   0.26
  Target-lesion revascularization                   8 (1.7%)                                  22 (2.2%)   0.52
  Target-vessel revascularization                   15 (3.1%)                                 40 (3.9%)   0.44
  Any coronary revascularization                    30 (6.2%)                                 79 (7.7%)   0.28
      Coronary-artery bypass grafting               1 (0.2%)                                  2 (0.2%)    0.96

Values are expressed as number (%).

Cumulative incidence was estimated by Kaplan-Meier method.

ACS = acute coronary syndrome; CAD = coronary artery disease; TIMI = Thrombolysis in Myocardial Infarction; GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries; MI = myocardial infarction; ST = stent thrombosis.

10.1371/journal.pone.0227612.t003

###### Unadjusted and adjusted risks of the ACS versus non-ACS and the effects of the risk-adjusting variables for the primary endpoint.

![](pone.0227612.t003){#pone.0227612.t003g}

                                Unadjusted          P value   Adjusted            P value
  ----------------------------- ------------------- --------- ------------------- ---------
  ACS                           0.75 (0.36--1.46)   0.41      0.94 (0.46--1.92)   0.87
  Age \> = 75 years             2.53 (1.38--4.76)   0.003     2.1 (1.11--3.94)    0.02
  Diabetes                      0.76 (0.39--1.42)   0.4       0.71 (0.37--1.36)   0.3
  Hemodialysis                  2.04 (0.49--5.62)   0.28      1.62 (0.49--5.36)   0.43
  Atrial fibrillation           2.53 (1.18--4.97)   0.02      2.03 (0.98--4.19)   0.06
  Prior myocardial infarction   1.48 (0.69--2.91)   0.29      1.54 (0.74--3.19)   0.24
  Peripheral vascular disease   3.14 (1.46--6.15)   0.005     2.54 (1.23--5.28)   0.01
  Statins use                   0.78 (0.4--1.67)    0.5       0.9 (0.43--1.88)    0.78

ACS = acute coronary syndrome, HR = hazard ratio, CI = confidence interval.

Clinical outcomes between 3- and 12-month {#sec014}
-----------------------------------------

Between 3- and 12-month, the cumulative incidence of the primary endpoint was not significantly different between the ACS and stable CAD groups (1.3% versus 2.4%, P = 0.16) ([Fig 5](#pone.0227612.g005){ref-type="fig"} and [Table 4](#pone.0227612.t004){ref-type="table"}). Regarding the major secondary endpoints, the cumulative incidences of TIMI major/minor bleeding and a composite of cardiovascular death, MI, stroke and definite ST were also not significantly different between the ACS and stable CAD groups. No patients had definite or probable ST between 3- and 12-month in both groups. Cumulative incidences of all-cause death, non-cardiac death and a composite of death or MI were significantly lower in the ACS group than in the stable CAD group ([Table 4](#pone.0227612.t004){ref-type="table"}).

![Cumulative incidence of the primary endpoint between 3-month and 12-month.\
Primary endpoint was defined as a composite of cardiovascular death, MI, stroke, definite ST and TIMI major/minor bleeding.](pone.0227612.g005){#pone.0227612.g005}

10.1371/journal.pone.0227612.t004

###### Clinical outcomes between 3-month and 12-month.

![](pone.0227612.t004){#pone.0227612.t004g}

                                                    No. of patients with at least one event   P Value     
  ------------------------------------------------- ----------------------------------------- ----------- ------
  Primary Endpoint                                  6 (1.3%)                                  24 (2.4%)   0.16
  Death                                                                                                   
      All-cause                                     2 (0.4%)                                  23 (2.2%)   0.01
      Cardiac death                                 1 (0.2%)                                  7 (0.7%)    0.24
      Cardiovascular death                          1 (0.2%)                                  7 (0.7%)    0.24
      Non-cardiac death                             1 (0.2%)                                  16 (1.6%)   0.02
  Myocardial infarction                             1 (0.2%)                                  1 (0.1%)    0.59
  Stroke                                                                                                  
      Any                                           1 (0.2%)                                  10 (1.0%)   0.1
      Ischemic                                      1 (0.2%)                                  8 (0.8%)    0.18
      Hemorrhagic                                   1 (0.2%)                                  2 (0.2%)    0.96
  Bleeding                                                                                                
      TIMI major                                    3 (0.6%)                                  7 (0.7%)    0.89
      TIMI minor/major                              4 (0.8%)                                  8 (0.8%)    0.92
      TIMI minimal/minor/major                      10 (2.1%)                                 16 (1.6%)   0.48
      GUSTO severe                                  3 (0.6%)                                  4 (0.4%)    0.54
      GUSTO moderate/severe                         3 (0.6%)                                  8 (0.8%)    0.73
  Definite stent thrombosis                         0 (0%)                                    0 (0%)      
  Stent thrombosis                                                                                        
      Possible                                      0 (0%)                                    6 (0.6%)    0.09
      Probable                                      0 (0%)                                    0 (0%)      
      Definite or probable                          0 (0%)                                    0 (0%)      
      Definite, probable or possible                0 (0%)                                    6 (0.6%)    0.09
  Death or myocardial infarction                    3 (0.6%)                                  24 (2.3%)   0.02
  Cardiovascular death or myocardial infarction     2 (0.4%)                                  8 (0.8%)    0.41
  Cardiovascular death, MI or stroke                3 (0.6%)                                  18 (1.8%)   0.08
  Cardiovascular death, MI, stroke or definite ST   3 (0.6%)                                  18 (1.8%)   0.08
  Target-lesion revascularization                   8 (1.7%)                                  21 (2.1%)   0.6
  Target-vessel revascularization                   15 (3.1%)                                 37 (3.6%)   0.61
  Any coronary revascularization                    29 (6.0%)                                 69 (6.8%)   0.56
      Coronary-artery bypass grafting               1 (0.2%)                                  2 (0.2%)    0.96

Values are expressed as number (%).

Cumulative incidence was estimated by Kaplan-Meier method.

Abbreviations are as in [Table 2](#pone.0227612.t002){ref-type="table"}.

Propensity matched analysis {#sec015}
---------------------------

As a sensitivity analysis, we compared the clinical outcomes between the ACS and stable CAD patients in the propensity matched cohort. Baseline characteristics were similar in terms of higher age, diabetes, hemodialysis, AF, prior MI, PVD and statin use between the 2 groups. Dyslipidemia, prior PCI and multivessel disease were more included in the stable CAD group, while current smoker were more often found in the ACS group ([S2 Table](#pone.0227612.s002){ref-type="supplementary-material"}). Cumulative 1-year incidence of the primary endpoint were similar between the ACS and stable CAD groups (2.3% versus 2.1%, P = 0.82) ([Fig 6](#pone.0227612.g006){ref-type="fig"} and [S3 Table](#pone.0227612.s003){ref-type="supplementary-material"}).

![Clinical outcomes at 1-year in the propensity matched cohort.\
Event rates indicated the cumulative 1-year incidence estimated by Kaplan-Meier method. Primary endpoint was defined as a composite of CV death, MI, stroke, definite ST and TIMI major/minor bleeding. ACS, acute coronary syndrome; CAD, coronary artery disease; CV death, cardiovascular death; MI, myocardial infarction; ST, stent thrombosis; TIMI, Thrombolysis in Myocardial Infarction.](pone.0227612.g006){#pone.0227612.g006}

Discussion {#sec016}
==========

The main finding of the current study is that stopping DAPT at 3-month after CoCr-EES implantation in patients with ACS was as safe as that in patients with stable CAD.

The current guidelines recommend 6-month DAPT after DES implantation in patients with stable CAD.\[[@pone.0227612.ref001],[@pone.0227612.ref002]\] However, there is a widely recognized notion that patients who presented with ACS have increased risk for subsequent atherothrombotic events as compared with those with stable CAD. Therefore, prolonged DAPT duration is recommended for more intensive prophylaxis for progressive atherothrombosis.\[[@pone.0227612.ref011],[@pone.0227612.ref012]\] Current recommendation of at least 1 year DAPT duration in ACS patients is based on the assumption that increased plaque vulnerability in ACS patients would be stabilized up to 1 year after the index ACS event. However, we previously reported that patients with acute myocardial infarction (AMI) as compared with those without AMI have similar cardiovascular event risk beyond 3 months after PCI, suggesting that stabilization of plaque vulnerability in ACS patients might have been achieved earlier than the currently assumed time period of 1 year.\[[@pone.0227612.ref013]\] In the meta-analyses of trials comparing DAPT duration after PCI, prolonged DAPT as compared with short DAPT was associated with increased risk of major bleeding and with a signal of increased mortality. \[[@pone.0227612.ref014],[@pone.0227612.ref015]\] Therefore, we have a reasonable rationale to explore shortening of the mandatory DAPT duration after DES implantation in ACS patients.

There is a scarcity of randomized trials exploring short DAPT in ACS patients. In the PCI-CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) study, long-term administration of clopidogrel after PCI in patients with non-ST elevation ACS was associated with a lower rate of cardiovascular death, MI, or any revascularization.\[[@pone.0227612.ref016]\] However, the study was conducted almost 20 years ago, when the implementation of the secondary preventive measures was much different from that in contemporary clinical practice. Furthermore, the study design of the PCI-CURE study might be flawed, because pretreatment of clopidogrel before PCI was implemented only in those patients assigned to long-term clopidogrel, but not in those patients assigned to placebo. In the SMART-DATE (Six-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes) trial, 6-month DAPT was non-inferior to 12-month DAPT in patients with ACS with new-generation DES in terms of a composite of all-cause death, MI, or stroke at 18 months (4.7% versus 4.2%, P for non-inferiority = 0.03).\[[@pone.0227612.ref017]\] In the DAPT-STEMI (Six Versus Twelve Months of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in ST-Elevation Myocardial Infarction) trial, 6-month DAPT was also non-inferior to 12-month DAPT in patients with STEMI undergoing PCI with zotarolimus-eluting stent in terms of the primary endpoint of a composite of all-cause mortality, MI, revascularization, stroke, and TIMI major bleeding at 18 months (4.8% versus 6.6%, P for non-inferiority = 0.004, and P for superiority = 0.26).\[[@pone.0227612.ref018]\] In contrast, in a network meta-analysis, 3-month DAPT, but not 6-month DAPT, was associated with higher rates of MI or ST as compared to 12-month DAPT in ACS patients, but not in stable CAD patients.\[[@pone.0227612.ref019]\] In this meta-analysis, data of the 3-month DAPT were derived from the RESET (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation), and the OPTIMIZE (Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice) randomized trials. \[[@pone.0227612.ref020],[@pone.0227612.ref021]\] In the RESET and OPTIMIZE trials, 3-month DAPT was evaluated with use of Endeavor^™^ zotarolimus-eluting stents, which has late lumen loss similar to BMS. CoCr-EES was reported to have significantly lower rates for ST as compared with BMS in patients with STEMI in the 1-year results of the EXAMINATION (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction) trial.\[[@pone.0227612.ref022]\] Therefore, the efficacy of short DAPT in ACS patients should be evaluated in those patients treated with new-generation DES, CoCr-EES in particular. The GLOBAL LEADERS trial explored the efficacy of the experimental regimen of 1-month DAPT followed by ticagrelor monotherapy as compared with the standard regimen of 12-month DAPT followed by aspirin monotheray in patients with stable CAD or ACS who underwent PCI with a biolimus A9-eluting stent.\[[@pone.0227612.ref023]\] Overall, the study failed to demonstrate the superiority of the experimental regimen for the primary endpoint of all-cause death or new Q-wave MI (rate ratio 0.87 \[95% CI 0.75--1.01\]; p = 0.073).\[[@pone.0227612.ref023]\] However in the ACS population, dropping aspirin beyond 1-month and continuing ticagrelor monotherapy was associated with a significantly lower risk for major bleeding with a trend for decreasing mortality at 1-year, suggesting that the current DAPT regimen with aspirin and ticagrelor for 1 year in ACS patients might be too intensive. \[[@pone.0227612.ref024]\]

In the present post-hoc analysis of the STOPDAPT trial demonstrated that 3-month DAPT after CoCr-EES implantation was associated with similarly low event rate for the primary endpoint without any definite ST events in both ACS and stable CAD patients, although 47% of ACS patients had troponin-negative UA at low-risk of event recurrence. Furthermore, the STOPDAPT trial had mostly enrolled stable patients after PCI, which might be one of the reasons for the low event rate even in ACS patients. Therefore, 3-month DAPT could be an option in selected patients with ACS in the new-generation DES era. In the STOPDAPT-2 trial including approximately 40% of ACS patients, 1-month DAPT followed by clopidogrel mono-therapy provided a net clinical benefit for ischemic and bleeding events over 12-month DAPT with aspirin and clopidogrel after CoCr-EES implantation.\[[@pone.0227612.ref025]\] The STOPDAPT-2 ACS trial are ongoing to evaluate 1-month DAPT followed by clopidogrel monotherapy as compared with 12-month DAPT with aspirin and clopidogrel in all-comer patients undergoing PCI using CoCr-EES (ClinicalTrials.gov: NCT03462498).

Study limitation {#sec017}
================

There are several important limitations in the current study. First, selection bias toward inclusion of patients with lower ischemic risk should be considered when interpreting the result of this study. Despite the all-comer study design, those ACS patients with large thrombotic burden and/or extensive atherosclerotic burden might well have not been included in this short DAPT trial. Indeed, patients with STEMI and NSTEMI were more often included in the non-enrolled group. Second, baseline characteristics were more complex in the stable CAD group than in the ACS group. Multivariable analysis might not be able to fully adjust the measured and unmeasured confounders. Third, patients received clopidogrel as a P2Y12 receptor blocker even in patients with ACS. Prasugrel or ticagrelor were not available in the enrollment period between 2012 and 2013 in Japan. Prasugrel or ticagrelor are generally preferred in ACS patients in the current clinical practice, especially in non-Asian patients. Fourth, as this study was conducted only in Japanese centers, the external validity to non-Asian patients would be limited. Finally, the sample size calculation was conducted for the main analysis, but not for this post-hoc analysis. Therefore, the number of patients enrolled in this study was underpowered, and not large enough to evaluate the low frequency event such as ST, especially in those with ACS.

Conclusion {#sec018}
==========

Stopping DAPT at 3 months after CoCr-EES implantation in patients with ACS including 47% of unstable angina was as safe as that in patients with stable CAD.

Supporting information {#sec019}
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Dear Dr. Kimura,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

All reviewers have raised serious concerns about the comparison between two very different populations (ACS vs non-ACS) in terms of baseline characteristics and the about low incidence of events in the ACS group, that mostly consists of patients with unstable angina. 

Reviewer 2 has raised concerns about population selection bias, that may hamper the generalizability of these results, and especially about the need to provide non-inferiority analysis rather than a superiority analysis. 

Reviewer 4 has raised concerns about the actual differences between ACS and stable patients and suggested to adjust for residual confounders by providing a propensity matching. 

All reviewers raised concerns about the actual risk of patients with ACS as compared to stable. CAD. Indeed, reviewers underline that the risk of events was higher in stable CAD patients and that ACS appears protective at univariate analysis, that is contraintutive.  

Statistical reviewer (Reviewer 3) has requested to upload data and codes to comply with Journal's guidelines and policy. 

I have concerns about the real need to compare two different populations from two different trials. Probably this part of the study should be omitted, else a complex propensity matching between patients from the different trials should be performed. 

We would appreciate receiving your revised manuscript by Nov 08 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppe Andò, M.D., Ph.D.

Academic Editor
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3\. Please confirm whether your Institutional Review Board specifically approved the study.

4.  Thank you for stating the following financial disclosure:

\'Abbott Vascular is the funding source of this study\'              

Please state what role the funders took in the study.  If the funders had no role, please state: \"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

If this statement is not correct you must amend it as needed.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: Yes

Reviewer \#4: Partly

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

Reviewer \#4: No

Reviewer \#5: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

Reviewer \#4: Yes

Reviewer \#5: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The submitted manuscript is a post-hoc analysis of the STOPDAPT trial, investigating the safety of a 3-month DAPT regimen after successful CoCr-EES implantation in patients with or without ACS. The authors aimed at evaluating if a short DAPT regimen is similarly safe in SCAD and ACS patients since those with an acute presentation have been traditionally considered at higher risk for recurrent thrombotic events and so in need for a more prolonged (at least 1-year) DAPT. The trial has a valid scientific ground, and methods and analyses are rigorously conducted. The authors concluded that "Stopping DAPT at 3-month after CoCr-EES implantation in patients with ACS was as safe as that in patients with stable CAD."

Detailed comments to be considered:

\- In the main paper published in 2016, a sub-group analysis investigating the ACS vs. non-ACS group already showed the absence of a significant interaction between clinical presentation and outcomes. Thus, these results are only confirmatory of previously published data. However, taking into account the recognized limits of sub-group analyses, the presented data are of potential interest addressing this issue with a more rigorous and detailed approach.

\- The rate of the primary endpoint events was similar in the two cohorts of patients. However, while the rate of events in the stable CAD group (3%) is in line with recent epidemiological studies, the rate of 1-year events for the ACS (2.3%) appears unusually low as compared with other reports, and less than half of the RESET cohort (4.8%) that was used as historical reference by the authors. Surprisingly, the rate of events results even higher (although only numerically) in the SCAD group compared with the ACS, which is difficult to justify biologically. This difference is even more evident at the land-mark analysis, where the risk of future events in SCAD is almost twice of that in ACS (2.4% s. 1.3%). These results might be at least in part related to the high prevalence of patients with unstable angina in the ACS group. Indeed, 1,266 patients out of 1,525 (83% of the total population) had a non-MI presentation, with only 44 patients having an NSTEMI. For this reason, no conclusions should be drawn for the ACS "troponin-positive" patients, which actually represent those at higher risk of recurrent thrombotic events and for which more concerns exist in the case of premature DAPT discontinuation. Accordingly, the present results cannot be applied to the whole ACS spectrum but limited to those at low-risk of event recurrence (comparable to those with SCAD). The authors should carefully discuss this point in the manuscript and be more cautious with their conclusions.

\- It is not clear which proportion of patients received intracoronary imaging to guide PCI. In the STOPDAPT-2, the (same) investigators reported a high rate of intracoronary imaging guidance according to the clinical practice in Japan. They stated \"\...the vast majority of patents in this study underwent PCI guided by intracoronary imaging devices, which are rarely used in the United States and Europe. Therefore, caution is warranted in extrapolating the current study results outside of Japan\". Please, clarify the percentage of patients receiving intracoronary imaging in the present analysis, also reporting data for stable CAD and ACS patients separately (if available).

\- Introduction: "However, it is unclear whether the distinction between ACS and stable CAD regarding the recommendation on the DAPT duration was based on a solid scientific rationale." This sentence should be probably reworded, as the scientific rationale for recommending a longer DAPT in patients with ACS, compared with those with stable CAD, is robust and based on the higher risk of future thrombotic events.

\- "Ethics" section: The full list of the individual centers participating in the trial can be reported in the supplementary appendix.

\- "Procedures" section: "Antiplatelet regimen included aspirin (≥81mg daily) ...". Which was the maximum dose of daily aspirin allowed in the trial? Did any patients receive ASA \>100 mg? Please, report these data (if available).

\- All patients enrolled in the trial were treated with clopidogrel. Please, briefly discuss the absence of patients receiving ticagrelor/prasugrel.

\- Endpoint and definition: In the era of high-sensitivity troponin, the diagnosis of UA is becoming rarer than in the past. Please clarify in the text which cardiac biomarkers were used for distinguishing UA vs NSTEMI, and how troponin was evaluated in the study (high-sensitivity?). Were the same methods for dosing cardiac biomarkers used across the 58 centers involved in the study (or not)? This might be a potential source of confounding in a multicentre study. Moreover, the proportion of UA patients appears very high in what the authors define as an all-comers population, also if compared with the STOPDAPT-2 population. The authors report in the flow-chart of the study that 2,054 patients were excluded (actually, more than those enrolled). Can the authors clarify which was the proportion of patients with an ACS (UA, STEMI, and NSTEMI) or SCAD in the \"non-enrolled\" population? We can assume most of these patients were excluded because presenting with STEMI or NSTEMI and then considered by the physicians at high-risk of complications if treated with a short DAPT. This (prudent) attitude by the investigators might have biased patients enrollment, resulting in a \"low-risk\" study population (substantially including UA and SCAD, and excluding STEMI and NSTEMI), for which the conclusions should be applied. In this context, it would be of interest if the authors could provide the GRACE score of the NSTE-ACS patients.

\- Statistical analysis: "Sample size calculation of this study was previously described." The sample size was previously described for the main analysis, and not for this post-hoc analysis. Conversely, the present analysis seems to be underpowered and non-conclusive for its purpose. Please clarify.

\- How were the patients on oral anticoagulants managed? Did the duration of DAPT in this subgroup differ from the rest of the population?

\- Conclusions: should be extended, and reworded to clarify that most of ACS patients were UA.

\- Please, better define which medications were considered among \"strong statins\".

\- Please, diffusely correct typos in the text: i.e., \"Statins use\" instead of \"Stains use\" in Table 3.

Reviewer \#2: In this study the authors aim at comparing the outcome in patients with ACS versus stable CAD undergoing PCI and subsequent double antiplatelet therapy (DAPT) with clopidogrel plus aspirin) for 3 months, followed by single antiplatelet therapy (SAPT) with aspirin for 12 months. Furthermore, the authors compared the clinical outcomes of the STOPDAPT trial with the RESET trial in both ACS and stable CAD patients. The authors concluded that a 3-month DAPT in ACS patients is as safe as in stable CAD patients.

The aim of this study is interesting; however, I have several comments to the authors.

Major comments:

• The authors stated that, among candidate patients, only those judged eligible by the physician were enrolled. In fact, among 3580 candidate patients, 2054 (far more than the half) were not enrolled. As the authors stated in the limitation section, this leads to a selection bias, that should be more clearly explained by the authors in discussing the results. Furthermore, as in a previous paper of the same trial (DOI 10.1007/s12928-015-0366-9), the main characteristics of not enrolled patients should be presented (also in appendix) or, at east, cited.

• Although the eligibility criteria of the RESET were comparable to those of the STOPDAPT, in the former study all patients with previous DES were excluded. Considering that, in RESET study, more patients that in STOPDAPT had previous PCI, a consistent number of patients in this study had a previous BMS implanted. Furthermore, in STOPDAPT only those judged eligible by the physician were enrolled. Importantly the baseline characteristics of the population of the two trials are strongly different (as shown in table s1), suggesting a higher risk profile in RESET population (more diabetics, more end stage CKD, more MVD...). This suggest that many confounders could bias the results and an adjustment through a propensity score should be performed before comparing the outcome of this two populations.

• There are significant differences between the ACS and stable CAD group in terms of many important variables (more AF, PAD, previous MI, Previous PCI/CABG, MVD in stable CAD group). Since these large differences between the two arms could be not adequately adjusted by a multivariable analysis, an adjustment throughout a propensity score would be a better option.

• The fact that in stable CAD 6 possible stent thrombosis occurred against 0 in ACS group clearly reflect a difference among the two populations. The same is for the difference, in terms death ((particularly non-cardiac death), between ACS and CAD at the landmark analysis. It is difficult to believe that that chronic CAD patients had a worse outcome.

• If the aim of the study is to demonstrate that, after an ACS, a 3-month DAPT after CoCr-EES implantation in patients with ACS is as safe as (or not less safe than) in stable CAD patients, a non-inferiority analysis should be planned. In fact, the non-significance at a superiority analysis cannot be used to demonstrate that there is not any significant difference between the two arms nor that an arm is not inferior to a second arm. This is particularly true for the endpoint for which the study is underpowered (e.g. stent thrombosis).

• It should be discussed that, for this study, the external validity to non-Asian patients is limited firstly because the study was conducted only in Japanese centres, secondly because the main P2Y12 inhibitor used was Clopidogrel (whereas ticagrelor or prasugrel should be generally preferred, especially in non-Asian patients)

Minor comments:

• In line 268, why do the authors use the plural form for STOPDAPT-2 ACS trial?

• I think that hyphens are sometimes incorrectly used. For example, in conclusion section, "Stopping DAPT at 3-month" should be replaced with "Stopping DAPT at 3 months".

Reviewer \#3: The manuscript addresses an interesting topic. The data are of certain interest and the employed methods are sound. The results might be very useful for future researchers.

Some comments follow.

1\. Data are not fully available. This is not in line with the journal\'s guidelines. Please, update the data and the code used to obtain parameters estimates. This would ensure the reproducibility of the results and allow the reviewers to check for the appropriateness of the methods.

2\. My main doubts concern some aspects of the modelling.

2a. Firstly, the authors must check for heterogeneity between centers. A major, and quite strong, assumption in the modelling is that patients belonging to different centers are homogeneous, i.e. no differences arise between multiple centers. Please, provide an extension of the modelling that takes into account for the presence of heterogeneity between centers. A random effects model may be an option.

2b. The use of Cox survival modelling is sound. Nevertheless, several assumptions must be fulfilled to ensure a proper statistical inference. It is desirable to determine whether a fitted Cox regression model adequately describes the data. I will briefly consider three kinds of diagnostics: for violation of the assumption of proportional hazards; for influential data; and for nonlinearity in the relationship between the log hazard and the covariates. Please, provide evidence that model assumptions are fulfilled or, if thery not, modify the model specification accordingly.

2c. As minor points: please explain the difference between adjusted and non-adjusted coefficients; furthermore, please consider a model selection procedure (e.g. LASSO) to identify the relevant variables.

Reviewer \#4: - In consideration of the relevant clinical and angiographic differences between the two compared groups, you have to perform a propensity pair-matched analysis, to increase accuracy of your results. Your current adjusted analysis is very limited and you have the number to perform a better analysis.

\- Events tended to be higher in the stable CAD groups, please provides analysis to better understand this greater risk.

\- You have to better explain what are the scientific and practical implications of your data and findings. Try to reinforce the overall meaning of your data.

Reviewer \#5: It is unclear how events occurred more often in the Stable CAD rather than in the ACS arm. ACS patients including NSTEMI and STEMI patients have a significantly higher risk of ischemic and bleeding complication compared to stable patients. This point should be thoroughly evaluated as it hampers to draft conclusion from this data. In fact ACS at univariate analysis seems tendentially protective from adverse events, which tend to lessen after adjustment. Ultimately it is not clear to this reviewer the comparison between ACS and SCAD for clinical events considering that due to more conservative patient selection in the ACS arm (see Table 1). STOPDAPT as a single arm study cannot either give information regarding the impact of different terms of DAPT duration.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Felice Gragnano

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: No

Reviewer \#5: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227612.r002

Author response to Decision Letter 0

17 Nov 2019

Responses to the editor's comments

We appreciate the kind editing and comments from the editor.

We amended the manuscript as suggested by the editor.

Editor:

I have concerns about the real need to compare two different populations from two different trials. Probably this part of the study should be omitted, else a complex propensity matching between patients from the different trials should be performed.

We appreciate the comments.

As the editor suggested, we omitted the comparison of two different populations from the STOPDAPT and RESET trials.

###### 

Submitted filename: Responses to reviewers STOPDAPT ACS final.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0227612.r003
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PONE-D-19-23933R1

One-year Clinical Outcomes of Patients With versus Without Acute Coronary Syndrome with 3-Month Duration of Dual Antiplatelet Therapy after Everolimus-eluting Stent Implantation

PLOS ONE

Dear Dr. Kimura,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

All reviewers appreciated your revised versions of the manuscript. While clinical reviewers do not have further  concerns, statistical reviewer asks to address a residual comment about the Cox model. Importantly, this comment will not influence the final decision to accept this manuscript.  

We would appreciate receiving your revised manuscript by Jan 17 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppe Andò, M.D., Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: No

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors addressed appropriately all the comments in the manuscript. No further comments are needed.

Reviewer \#2: All my comments have been addressed.

Reviewer \#3: Thank you very for having addressed most of the comments I raised.

One point needs still to be addressed. Influential observations and nonlinearities in the Cox model should be analysed. Yhe martingale residuals may be plotted against covariates to detect nonlinearity, and may

also be used to form component-plus-residual (or partial-residual) plots, again in the manner of linear and

generalized linear models. A matrix of estimated changes in the regression coefficients upon deleting each observation in turn may be used to detect influential observations.

Reviewer \#4: Reviewer comments were addressed and the manuscript has been improved. I have no further comments.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Marco Di Maio

Reviewer \#3: No

Reviewer \#4: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227612.r004

Author response to Decision Letter 1

18 Dec 2019

Responses to the reviewer's comments

We appreciate the kind editing and comments from the editor and the reviewers.

Reviewer \#3:

One point needs still to be addressed. Influential observations and nonlinearities in the Cox model should be analyzed. Yhe martingale residuals may be plotted against covariates to detect nonlinearity, and may also be used to form component-plus-residual (or partial-residual) plots, again in the manner of linear and generalized linear models. A matrix of estimated changes in the regression coefficients upon deleting each observation in turn may be used to detect influential observations.

Thank you very much for your comment.

As reviewer commented, influential observations and nonlinearities in the Cox model could be analyzed. Proportional hazard assumptions for the risk-adjusting variables were assessed on the plots of log (time) versus log \[-log (survival)\] stratified by the variable. The assumptions were verified to be acceptable for all the variables. We thus here show the plots for age, atrial fibrillation (AF), and peripheral vascular disease (PVD) because these variables had smaller p-values.

The main comparison of this study is ACS versus non-ACS patients, and thus other covariates are used for adjustment in the multivariate models and not relevant to the main results of this study. Therefore, the detailed inspections for residuals or linearity are not considered relevant to the manuscript and they do not affect on our results. However, we are happy to conduct these analyses if the editors and reviewers considered it necessary to accept our manuscript.
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Submitted filename: Responses to reviewers STOPDAPT ACS revise2 final version.docx
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Click here for additional data file.
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PONE-D-19-23933R2

Dear Dr. Kimura,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Giuseppe Andò, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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PONE-D-19-23933R2

One-year Clinical Outcomes of Patients With versus Without Acute Coronary Syndrome with 3-Month Duration of Dual Antiplatelet Therapy after Everolimus-eluting Stent Implantation

Dear Dr. Kimura:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Giuseppe Andò

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**Takeshi Kimura, Keiichi Igarashi, Kazushige Kadota, Kengo Tanabe, Yoshihiro Morino, and Ken Kozuma were advisory board members of Abbott Vascular. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

[^2]: ¶ Membership listed in the acknowledgments.
